利妥昔单抗治疗嗜酸性肉芽肿性多血管炎的疗效与安全性
6、12、24个月改善率分别为76.8%、82.8%、93.2%,但24个月内复发率达54%,以哮喘最常见;ANCA阳性者哮喘/ENT复发无生存期更长、缓解更快。
要点
- 利妥昔单抗对EGPA有一定疗效,24个月改善率达93.2%
- 24个月内复发率54%,哮喘为最常见复发表现
- ANCA阳性者哮喘/ENT复发无生存期更长且缓解更快
核心结论
- 利妥昔单抗在EGPA中显示一定疗效并减少泼尼松需求,但哮喘和ENT复发率较高。
- ANCA阳性亚组在孤立性哮喘/ENT加重方面反应更持久。
研究设计与样本
- 在初始治疗时及每3个月收集标准化数据至24个月。
主要发现
- 6、12、24个月改善(完全+部分)率分别为76.8%、82.8%、93.2%。
- 24个月内54%患者复发,哮喘为最常见表现。
- 中位BVAS从基线6降至6个月1、12和24个月0。
- 中位泼尼松剂量(mg/日)从12.5分别降至6个月7、12个月7.5、24个月5。
- ANCA阳性患者哮喘/ENT复发无生存期更长、缓解时间更短。
关键数值与推荐
- 应答定义为BVAS=0,部分应答定义为BVAS较基线下降≥50%。
- 缓解定义为BVAS=0且泼尼松剂量≤5 mg。
临床怎么用
- 利妥昔单抗可用于难治性或环磷酰胺禁忌的EGPA,有助于减少泼尼松用量。
- 治疗期间需关注哮喘和ENT复发,尤其ANCA阴性患者。
局限性
- 单中心回顾性设计,样本量有限。
- 缺乏对照组,无法与环磷酰胺等标准治疗直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, clinical features and treatment responses. Rituximab is a licensed therapy for granulomatosis with polyangiitis and microscopic polyangiitis but there is limited experience of rituximab in EGPA. METHODS: EGPA patients from a tertiary centre who received rituximab for mostly refractory EGPA or in whom cyclophosphamide was contra indicated were studied. A standardised dataset was collected at time of initial treatment and every 3 months for 24 months. Response was defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 and partial response as ≥50% reduction in BVAS from baseline. Remission was defined as a BVAS of 0 on prednisolone dose ≤5 mg. RESULTS: Sixty-nine patients (44 female) received rituximab between 2003 and 2017. Improvement (response and partial response) was observed in 76.8% of patients at 6 months, 82.8% at 12 months and in 93.2% by 24 months, while relapses occurred in 54% by 24 months, with asthma being the most frequent manifestation. The median BVAS decreased from 6 at baseline to 1 at 6 months, and 0 at 12 and 24 months. Prednisolone dose (mg/day, median) decreased from 12.5 to 7, 7.5 and 5 at 6, 12 and 24 months, respectively. ANCA positive patients had a longer asthma/ear, nose and throat (ENT) relapse-free survival time and a shorter time to remission. DISCUSSION: Rituximab demonstrated some efficacy in EGPA and led to a reduction in prednisolone requirement, but asthma and ENT relapse rates were high despite continued treatment. The ANCA positive subset appeared to have a more sustained response on isolated asthma/ENT exacerbations.
引用
- Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019. PMID: 31245051. doi:10.1136/rmdopen-2019-000905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。